CN103154031A - 利用il-17拮抗剂治疗牛皮癣的方法 - Google Patents

利用il-17拮抗剂治疗牛皮癣的方法 Download PDF

Info

Publication number
CN103154031A
CN103154031A CN2011800487322A CN201180048732A CN103154031A CN 103154031 A CN103154031 A CN 103154031A CN 2011800487322 A CN2011800487322 A CN 2011800487322A CN 201180048732 A CN201180048732 A CN 201180048732A CN 103154031 A CN103154031 A CN 103154031A
Authority
CN
China
Prior art keywords
binding molecule
patient
regimen
dose
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800487322A
Other languages
English (en)
Chinese (zh)
Inventor
A·盖特纳
M·马哈切克
C·帕帕瓦西利斯
O·桑德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44759699&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103154031(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Priority to CN201710261381.2A priority Critical patent/CN107029234A/zh
Publication of CN103154031A publication Critical patent/CN103154031A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2011800487322A 2010-10-08 2011-10-07 利用il-17拮抗剂治疗牛皮癣的方法 Pending CN103154031A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710261381.2A CN107029234A (zh) 2010-10-08 2011-10-07 利用il‑17拮抗剂治疗牛皮癣的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39138810P 2010-10-08 2010-10-08
US61/391,388 2010-10-08
PCT/EP2011/067522 WO2012045848A1 (en) 2010-10-08 2011-10-07 Methods of treating psoriasis using il-17 antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201710261381.2A Division CN107029234A (zh) 2010-10-08 2011-10-07 利用il‑17拮抗剂治疗牛皮癣的方法

Publications (1)

Publication Number Publication Date
CN103154031A true CN103154031A (zh) 2013-06-12

Family

ID=44759699

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2011800487322A Pending CN103154031A (zh) 2010-10-08 2011-10-07 利用il-17拮抗剂治疗牛皮癣的方法
CN201710261381.2A Pending CN107029234A (zh) 2010-10-08 2011-10-07 利用il‑17拮抗剂治疗牛皮癣的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201710261381.2A Pending CN107029234A (zh) 2010-10-08 2011-10-07 利用il‑17拮抗剂治疗牛皮癣的方法

Country Status (28)

Country Link
US (9) US9717791B2 (enExample)
EP (4) EP3792281A1 (enExample)
JP (2) JP5537740B2 (enExample)
KR (3) KR20150018595A (enExample)
CN (2) CN103154031A (enExample)
AU (1) AU2011311482B2 (enExample)
BR (1) BR112013008501A2 (enExample)
CA (1) CA2813900C (enExample)
CL (1) CL2013000930A1 (enExample)
CY (1) CY1119942T1 (enExample)
DK (1) DK2625199T3 (enExample)
ES (1) ES2660770T3 (enExample)
HK (1) HK1247932A1 (enExample)
HR (1) HRP20180301T1 (enExample)
HU (1) HUE038334T2 (enExample)
IL (1) IL225310A (enExample)
LT (1) LT2625199T (enExample)
MA (1) MA34646B1 (enExample)
MX (1) MX356279B (enExample)
NO (1) NO2625199T3 (enExample)
PH (1) PH12013500660B1 (enExample)
PL (1) PL2625199T3 (enExample)
PT (1) PT2625199T (enExample)
RU (2) RU2665954C1 (enExample)
SG (1) SG188979A1 (enExample)
SI (1) SI2625199T1 (enExample)
TW (2) TWI564022B (enExample)
WO (1) WO2012045848A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104011223A (zh) * 2011-11-21 2014-08-27 诺华股份有限公司 使用il-17拮抗剂及psa应答或非应答等位基因治疗银屑病性关节炎(psa)的方法
CN106573059A (zh) * 2014-08-26 2017-04-19 麒麟-安姆根有限公司 接受过抗TNF‑α抗体疗法的银屑病患者的治疗方法
CN114249826A (zh) * 2014-12-22 2022-03-29 诺华股份有限公司 Il-17抗体中半胱氨酸残基的选择性还原
WO2023186174A1 (en) * 2022-04-01 2023-10-05 Zai Lab (Shanghai) Co., Ltd. Topical formulation comprising an il-17a binding molecule and uses thereof
US12485173B2 (en) 2014-12-22 2025-12-02 Novartis Ag Pharmaceutical products and stable liquid compositions of IL-17 antibodies

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
WO2011088120A1 (en) 2010-01-15 2011-07-21 Amgen Inc. Antibody formulation and therapeutic regimens
AU2011254557B2 (en) 2010-05-20 2015-09-03 Ablynx Nv Biological materials related to HER3
HUE044038T2 (hu) 2010-11-05 2019-09-30 Novartis Ag Spondilitisz ankilopoetika kezelési eljárásai anti-IL-17 alkalmazásával
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
AU2014228553B2 (en) * 2013-03-15 2019-01-24 Amgen Inc. Methods for treating Crohn's disease using an anti-IL23 antibody
US20160060337A1 (en) * 2013-03-15 2016-03-03 Amgen Inc. Methods for treating psoriasis using an anti-il-23 antibody
WO2015022656A1 (en) 2013-08-15 2015-02-19 Novartis Ag Methods of treating generalized pustular psoriasis (gpp) using il-17 antagonists
US11421025B2 (en) 2013-12-27 2022-08-23 Osaka University Treatment of IL-17A diseases
RU2577228C2 (ru) * 2014-03-14 2016-03-10 Закрытое Акционерное Общество "Биокад" Анти-il-17-антитела, способ их получения и способ применения
JP6596014B2 (ja) * 2014-03-31 2019-10-23 アムジェン ケー・エー，インコーポレイテッド 爪および頭皮乾癬の治療方法
US11548940B2 (en) * 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
AU2015258859B2 (en) 2014-05-15 2020-07-23 Rani Therapeutics, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
KR20230170796A (ko) * 2014-09-10 2023-12-19 노파르티스 아게 건선성 관절염 환자에서 구조적 손상의 진행을 억제하기 위한 il-17 길항제의 용도
EP3265493B1 (en) 2015-03-02 2024-01-10 180 Therapeutics LP Method of treating a localized fibrotic disorder using an il-33 antagonist
EP3167892A1 (en) 2015-11-10 2017-05-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for preventing or treating imflammatory bowel diseases
MY206805A (en) * 2015-10-27 2025-01-08 UCB Biopharma SRL Methods of treatment using anti-il-17a/f antibodies
ES2992409T3 (es) * 2016-07-19 2024-12-12 Novartis Ag Métodos de tratamiento de la psoriasis en placas de nueva aparición usando antagonistas de IL-17
WO2018096467A1 (en) * 2016-11-28 2018-05-31 Novartis Ag Methods of treating acne using interleukin-17 (il-17) antagonists
WO2018158741A1 (en) * 2017-03-03 2018-09-07 Novartis Ag Psoriasis disease modification following long-term treatment with an il-17 antagonist
CN111032691A (zh) * 2017-08-23 2020-04-17 伊莱利利公司 生殖器银屑病的治疗
TWI808397B (zh) * 2018-09-11 2023-07-11 美商美國禮來大藥廠 治療牛皮癬之方法
US20220267432A1 (en) 2019-07-30 2022-08-25 Jiangsu Hengrui Medicine Co., Ltd. Method for treating autoimmune disease by il-17 antagonist
BR112022004941A2 (pt) 2019-09-20 2022-06-28 Novartis Ag Métodos para tratar doenças autoimunes com o uso de antagonistas de interleucina-17 (il-17)
WO2022127842A1 (zh) * 2020-12-17 2022-06-23 上海华奥泰生物药业股份有限公司 靶向il-17a和il-36r的双特异性抗体及其应用
TW202246329A (zh) * 2021-03-03 2022-12-01 大陸商蘇州盛迪亞生物醫藥有限公司 抗il-17抗體治療自體免疫性疾病和炎症的方法
CN116593718B (zh) * 2023-07-18 2023-09-15 军科正源（北京）药物研究有限责任公司 用于检测司库奇尤单抗抗药性抗体的试剂

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006013107A1 (en) * 2004-08-05 2006-02-09 Novartis Ag Il-17 antagonistic antibodies

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9422306D0 (en) * 1994-11-04 1994-12-21 Sandoz Ltd Organic compounds
US6093745A (en) * 1997-11-25 2000-07-25 Psorx, L.L.C. Methods and composition for treating skin proliferative diseases
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders
US20090280065A1 (en) * 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
TWI439284B (zh) * 2004-04-09 2014-06-01 Abbvie Biotechnology Ltd 用於治療ＴＮＦα相關失調症之多重可變劑量療法
JP2009507023A (ja) * 2005-09-01 2009-02-19 シェーリング コーポレイション 自己免疫性眼炎症性疾患を処置するためのｉｌ−２３およびｉｌ−１７のアンタゴニストの使用
ES2672221T3 (es) * 2005-12-13 2018-06-13 Eli Lilly And Company Anticuerpos anti IL-17
TW200815469A (en) * 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
RU2367429C2 (ru) 2007-01-30 2009-09-20 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Способ лечения псориаза
EP2152318A4 (en) * 2007-06-01 2011-12-07 Abbott Biotech Ltd COMPOSITIONS AND USES FOR THE TREATMENT OF PSORIASIS AND CROHN'S DISEASE
RU2341272C1 (ru) * 2007-10-22 2008-12-20 Левон Никитович Мкртчян Средство для неспецифической иммунотерапии
UA103499C2 (ru) * 2008-09-29 2013-10-25 Рош Глікарт Аг Антитело против интерлейкина-17 (ил-17) человека и его применение

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006013107A1 (en) * 2004-08-05 2006-02-09 Novartis Ag Il-17 antagonistic antibodies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALAN MENTER,MD ET AL.: "Adalimumab therapy for moderate to severe psoriasis:A randomized, controlled phaseIII trial", 《J AM ACAD DERMATOL》, vol. 58, no. 1, 31 January 2008 (2008-01-31), pages 106 - 115, XP022395589, DOI: doi:10.1016/j.jaad.2007.09.010 *
KENNETH B.GORDON,MD ET AL.: "Clinical response to adalimumab treatment in patients with moderate to severe psoriasis:Double-blind, randomized controlled trial and open-label extension study", 《J AM ACAD DERMATOL》, vol. 55, no. 4, 31 October 2006 (2006-10-31), pages 598 - 606 *
WOLFGANG HUEBER ET AL.: "Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis", 《SCIENCE TRANSLATIONAL MEDICINE》, vol. 2, no. 52, 6 October 2010 (2010-10-06) *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104011223A (zh) * 2011-11-21 2014-08-27 诺华股份有限公司 使用il-17拮抗剂及psa应答或非应答等位基因治疗银屑病性关节炎(psa)的方法
CN106573059A (zh) * 2014-08-26 2017-04-19 麒麟-安姆根有限公司 接受过抗TNF‑α抗体疗法的银屑病患者的治疗方法
CN114249826A (zh) * 2014-12-22 2022-03-29 诺华股份有限公司 Il-17抗体中半胱氨酸残基的选择性还原
CN114249826B (zh) * 2014-12-22 2024-02-02 诺华股份有限公司 Il-17抗体中半胱氨酸残基的选择性还原
US12485173B2 (en) 2014-12-22 2025-12-02 Novartis Ag Pharmaceutical products and stable liquid compositions of IL-17 antibodies
US12485172B2 (en) 2014-12-22 2025-12-02 Novartis Ag Pharmaceutical products and stable liquid compositions of IL-17 antibodies
WO2023186174A1 (en) * 2022-04-01 2023-10-05 Zai Lab (Shanghai) Co., Ltd. Topical formulation comprising an il-17a binding molecule and uses thereof

Also Published As

Publication number Publication date
US20230321231A1 (en) 2023-10-12
CA2813900C (en) 2017-01-10
HK1247932A1 (en) 2018-10-05
EP2625199A1 (en) 2013-08-14
JP5537740B2 (ja) 2014-07-02
PT2625199T (pt) 2018-02-28
EP3792281A1 (en) 2021-03-17
PH12013500660A1 (en) 2013-05-20
NO2625199T3 (enExample) 2018-04-21
US20170304439A1 (en) 2017-10-26
KR20150018595A (ko) 2015-02-23
US9717791B2 (en) 2017-08-01
PH12013500660B1 (en) 2017-10-27
HRP20180301T1 (hr) 2018-03-23
JP2014114288A (ja) 2014-06-26
HUE038334T2 (hu) 2018-10-29
ES2660770T3 (es) 2018-03-26
CY1119942T1 (el) 2018-12-12
RU2665954C1 (ru) 2018-09-05
KR101620771B1 (ko) 2016-05-12
CL2013000930A1 (es) 2014-03-28
US20200171147A1 (en) 2020-06-04
TW201630625A (zh) 2016-09-01
TW201216984A (en) 2012-05-01
JP2013543501A (ja) 2013-12-05
WO2012045848A1 (en) 2012-04-12
EP4137514A1 (en) 2023-02-22
MX356279B (es) 2018-05-22
EP3299390A1 (en) 2018-03-28
US20250161445A1 (en) 2025-05-22
US10583190B2 (en) 2020-03-10
DK2625199T3 (en) 2018-02-26
IL225310A0 (en) 2013-06-27
CN107029234A (zh) 2017-08-11
EP2625199B1 (en) 2017-11-22
LT2625199T (lt) 2018-03-12
BR112013008501A2 (pt) 2016-08-16
MX2013003916A (es) 2013-06-03
US20250161443A1 (en) 2025-05-22
US20210113688A1 (en) 2021-04-22
US11534490B2 (en) 2022-12-27
CA2813900A1 (en) 2012-04-12
RU2013120957A (ru) 2014-11-20
SI2625199T1 (en) 2018-03-30
KR20140097566A (ko) 2014-08-06
US20250161444A1 (en) 2025-05-22
PL2625199T3 (pl) 2018-04-30
IL225310A (en) 2016-10-31
TWI564022B (zh) 2017-01-01
RU2591083C2 (ru) 2016-07-10
AU2011311482A1 (en) 2013-04-04
US20130202610A1 (en) 2013-08-08
MA34646B1 (fr) 2013-11-02
TWI548419B (zh) 2016-09-11
US20210162044A1 (en) 2021-06-03
KR20130110179A (ko) 2013-10-08
SG188979A1 (en) 2013-05-31
AU2011311482B2 (en) 2014-05-29

Similar Documents

Publication Publication Date Title
US20250161444A1 (en) Methods of treating psoriasis using il-17 antagonists
JP2024109762A (ja) Ｉｌ－１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法
US20230321232A1 (en) Methods of treating generalized pustular psoriasis (gpp) using il-17 antagonists
WO2018158741A1 (en) Psoriasis disease modification following long-term treatment with an il-17 antagonist
HK40037862A (en) Methods of treating psoriasis using il-17 antagonists
HK40088403A (en) Methods of treating psoriasis using il-17 antagonists
HK1183673A (en) Methods of treating psoriasis using il-17 antagonists
HK1183673B (en) Methods of treating psoriasis using il-17 antagonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20130612

RJ01 Rejection of invention patent application after publication